[EN] HETEROCYCLIC GLP-1 AGONISTS [FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1
摘要:
The present disclosure relates generally to GLP-1 agonists and pharmaceutical compositions comprising the same, as well as methods for treating a GLP-1 associated disease, disorder, or condition.
[EN] NEW 6-MEMBERED HETEROAROMATIC SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE CYANOINDOLINE À SUBSTITUTION HÉTÉROAROMATIQUE À 6 CHAÎNONS UTILISÉS COMME INHIBITEURS DE NIK
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017125534A1
公开(公告)日:2017-07-27
The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
[EN] PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE<br/>[FR] DÉRIVÉS DE PYRROLIDIONE UTILES COMME INHIBITEURS DE LA KINASE D'INDUCTION DE NF-KB
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2023217879A1
公开(公告)日:2023-11-16
The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventing or treating diseases such as but not limited to inflammatory disorders and autoimmune disorders.